Literature DB >> 18405996

DC-SIGN enhances infection of cells with glycosylated West Nile virus in vitro and virus replication in human dendritic cells induces production of IFN-alpha and TNF-alpha.

Byron E E Martina1, Penelopie Koraka, Petra van den Doel, Guus F Rimmelzwaan, Bart L Haagmans, Albert D M E Osterhaus.   

Abstract

The recent introduction of West Nile virus (WNV) into the Western hemisphere resulted in significant human outbreaks causing disease of variable severity. Previous studies classified WNV into two major lineages (L1 and L2) that differ in their virulence. Since most L1 strains are glycosylated, we investigated the role of dendritic cell-specific ICAM-3-grabbing non-integrin (DC-SIGN) in infection efficiency of glycosylated WNV strains. We showed that glycosylated strains, in contrast to non-glycosylated strains, infected DC-SIGN expressing cells more efficiently than DC-SIGN negative cells. Furthermore, WNV can productively infect cultured human dendritic cells (DCs) and infection of dendritic cells with the glycosylated WNV-NY99 L1 strain induced production of significantly more TNF-alpha and IFN-alpha in cultured DC, than infection with the non-glycosylated B956 L2 strain. Together, these results indicate that DC-SIGN enhances infection of cells by WNV glycosylated strains, which may at least in part explain the higher pathogenicity of glycosylated L1 strains versus most non-glycosylated L2 strains.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18405996     DOI: 10.1016/j.virusres.2008.02.008

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  33 in total

Review 1.  Cell-intrinsic innate immune control of West Nile virus infection.

Authors:  Michael S Diamond; Michael Gale
Journal:  Trends Immunol       Date:  2012-06-20       Impact factor: 16.687

Review 2.  The contribution of rodent models to the pathological assessment of flaviviral infections of the central nervous system.

Authors:  David C Clark; Aaron C Brault; Elizabeth Hunsperger
Journal:  Arch Virol       Date:  2012-05-17       Impact factor: 2.574

Review 3.  Innate host responses to West Nile virus: Implications for central nervous system immunopathology.

Authors:  Giada Rossini; Maria Paola Landini; Francesco Gelsomino; Vittorio Sambri; Stefania Varani
Journal:  World J Virol       Date:  2013-05-12

4.  Envelope Protein Glycosylation Mediates Zika Virus Pathogenesis.

Authors:  Derek L Carbaugh; Ralph S Baric; Helen M Lazear
Journal:  J Virol       Date:  2019-05-29       Impact factor: 5.103

Review 5.  Flavivirus Envelope Protein Glycosylation: Impacts on Viral Infection and Pathogenesis.

Authors:  Derek L Carbaugh; Helen M Lazear
Journal:  J Virol       Date:  2020-05-18       Impact factor: 5.103

6.  Keratinocytes are cell targets of West Nile virus in vivo.

Authors:  Pei-Yin Lim; Melissa J Behr; Chrystal M Chadwick; Pei-Yong Shi; Kristen A Bernard
Journal:  J Virol       Date:  2011-03-02       Impact factor: 5.103

Review 7.  Molecular mechanisms involved in the early steps of flavivirus cell entry.

Authors:  Bärbel Kaufmann; Michael G Rossmann
Journal:  Microbes Infect       Date:  2010-12-10       Impact factor: 2.700

Review 8.  West Nile virus infection and immunity.

Authors:  Mehul S Suthar; Michael S Diamond; Michael Gale
Journal:  Nat Rev Microbiol       Date:  2013-02       Impact factor: 60.633

9.  Interferon regulatory factor IRF-7 induces the antiviral alpha interferon response and protects against lethal West Nile virus infection.

Authors:  Stephane Daffis; Melanie A Samuel; Mehul S Suthar; Brian C Keller; Michael Gale; Michael S Diamond
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

10.  Induction of IFN-beta and the innate antiviral response in myeloid cells occurs through an IPS-1-dependent signal that does not require IRF-3 and IRF-7.

Authors:  Stephane Daffis; Mehul S Suthar; Kristy J Szretter; Michael Gale; Michael S Diamond
Journal:  PLoS Pathog       Date:  2009-10-02       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.